期刊
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
卷 8, 期 4, 页码 299-306出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-013-0184-z
关键词
Myeloproliferative neoplasms; JAK2; Clonal evolution; Oncogene; Tumor suppressor; Hematologicmalignancy
资金
- Austrian Science Fund [P23257-B12]
- MPN Research Foundation
- Austrian Science Fund (FWF) [P23257] Funding Source: Austrian Science Fund (FWF)
- Austrian Science Fund (FWF) [P 23257] Funding Source: researchfish
The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells. Clonal evolution, disease initiation and progression are influenced by genetic alterations, often affecting cytokine signaling and gene expression. This review outlines somatic changes discovered in myeloproliferative neoplasms and how these genetic aberrations influence the pathogenesis of myeloproliferative neoplasms. Furthermore, genetic responses to drug treatments in myeloproliferative neoplasms are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据